Back to search results

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma · Recurrent Mantle Cell Lymphoma · Recurrent Marginal Zone Lymphoma · Recurrent Small Lymphocytic Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Refractory Diffuse Large B-Cell Lymphoma · Refractory Follicular Lymphoma · Refractory Mantle Cell Lymphoma · Refractory Marginal Zone Lymphoma · Refractory Small Lymphocytic Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Mohamed A. Kharfan-Dabaja, M.D., M.B.A.)
Study leads

  • Mohamed A. Kharfan-Dabaja, M.D., M.B.A.

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)